The LINC00519/hsa-miR-22-3p/MECOM Axis Accelerates Intrahepatic Cholangiocarcinoma Progression through PI3K/AKT...

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Intrahepatic cholangiocarcinoma (ICC) is the second most prevalent liver cancer.
• Long non-coding RNA LINC00519 is implicated in the progression of various cancers.

Purpose of the Study:

• To elucidate the molecular mechanism of LINC00519 in ICC progression.
• To investigate the regulatory axis LINC00519/hsa-miR-22-3p/MECOM and its impact on the PI3K/AKT pathway in ICC.

Main Methods:

• Expression analysis using the ENCORI database and quantitative real-time PCR.
• Functional assays including clone formation, Transwell, flow cytometry, and Western blot.
• Mechanism determination via dual-luciferase reporter assay and rescue experiments.

Main Results:

• LINC00519 and MECOM were upregulated, while hsa-miR-22-3p was downregulated in ICC.
• LINC00519 silencing inhibited ICC cell proliferation and migration, and induced apoptosis, partly via the PI3K/AKT pathway.
• LINC00519 functions as a competing endogenous RNA targeting MECOM by sponging hsa-miR-22-3p.

Conclusions:

• A novel LINC00519/hsa-miR-22-3p/MECOM regulatory axis and the PI3K/AKT pathway are crucial in modulating ICC progression.
• This study provides a deeper understanding of the non-coding RNA regulatory network in ICC.
• The identified axis and pathway represent potential targets for ICC diagnosis and targeted therapy.